Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 500 versus HYDRO SERP 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 500 versus HYDRO SERP 50.
DIUPRES-500 vs HYDRO-SERP "50"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
Hydrochlorothiazide 50 mg orally once daily.
None Documented
None Documented
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination